These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 34302274)

  • 1. Current hurdles to the translation of nanomedicines from bench to the clinic.
    Đorđević S; Gonzalez MM; Conejos-Sánchez I; Carreira B; Pozzi S; Acúrcio RC; Satchi-Fainaro R; Florindo HF; Vicent MJ
    Drug Deliv Transl Res; 2022 Mar; 12(3):500-525. PubMed ID: 34302274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities.
    Agrahari V; Agrahari V
    Drug Discov Today; 2018 May; 23(5):974-991. PubMed ID: 29406263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development.
    Csóka I; Ismail R; Jójárt-Laczkovich O; Pallagi E
    Curr Med Chem; 2021; 28(36):7461-7476. PubMed ID: 33823761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation.
    Taha MS; Padmakumar S; Singh A; Amiji MM
    Drug Deliv Transl Res; 2020 Jun; 10(3):766-790. PubMed ID: 32170656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges in development of nanoparticle-based therapeutics.
    Desai N
    AAPS J; 2012 Jun; 14(2):282-95. PubMed ID: 22407288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
    Patel P; Shah J
    Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A translational framework to DELIVER nanomedicines to the clinic.
    Joyce P; Allen CJ; Alonso MJ; Ashford M; Bradbury MS; Germain M; Kavallaris M; Langer R; Lammers T; Peracchia MT; Popat A; Prestidge CA; Rijcken CJF; Sarmento B; Schmid RB; Schroeder A; Subramaniam S; Thorn CR; Whitehead KA; Zhao CX; Santos HA
    Nat Nanotechnol; 2024 Nov; 19(11):1597-1611. PubMed ID: 39242807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges associated and approaches for successful translation of nanomedicines into commercial products.
    Agrahari V; Hiremath P
    Nanomedicine (Lond); 2017 Apr; 12(8):819-823. PubMed ID: 28338401
    [No Abstract]   [Full Text] [Related]  

  • 9. The nanomedicines alliance: an industry perspective on nanomedicines.
    Malinoski FJ
    Nanomedicine; 2014 Nov; 10(8):1819-20. PubMed ID: 25038497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomedicines: From Bench to Bedside and Beyond.
    Havel H; Finch G; Strode P; Wolfgang M; Zale S; Bobe I; Youssoufian H; Peterson M; Liu M
    AAPS J; 2016 Nov; 18(6):1373-1378. PubMed ID: 27480318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
    Hock SC; Ying YM; Wah CL
    PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicines: The magic bullets reaching their target?
    Flühmann B; Ntai I; Borchard G; Simoens S; Mühlebach S
    Eur J Pharm Sci; 2019 Feb; 128():73-80. PubMed ID: 30465818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translational Multi-Disciplinary Approach for the Drug and Gene Delivery Systems for Cancer Treatment.
    Nayak R; Meerovich I; Dash AK
    AAPS PharmSciTech; 2019 Apr; 20(4):160. PubMed ID: 30968269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asymmetric-flow field-flow fractionation for measuring particle size, drug loading and (in)stability of nanopharmaceuticals. The joint view of European Union Nanomedicine Characterization Laboratory and National Cancer Institute - Nanotechnology Characterization Laboratory.
    Caputo F; Mehn D; Clogston JD; Rösslein M; Prina-Mello A; Borgos SE; Gioria S; Calzolai L
    J Chromatogr A; 2021 Jan; 1635():461767. PubMed ID: 33310281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanomedicine at the crossroads - A quick guide for IVIVC.
    Mast MP; Modh H; Champanhac C; Wang JW; Storm G; Krämer J; Mailänder V; Pastorin G; Wacker MG
    Adv Drug Deliv Rev; 2021 Dec; 179():113829. PubMed ID: 34174332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of nanomedicines: A reflection on a field under construction needed for clinical translation success.
    Coty JB; Vauthier C
    J Control Release; 2018 Apr; 275():254-268. PubMed ID: 29454063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures.
    Ragelle H; Danhier F; Préat V; Langer R; Anderson DG
    Expert Opin Drug Deliv; 2017 Jul; 14(7):851-864. PubMed ID: 27730820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer nanomedicine: a review of recent success in drug delivery.
    Tran S; DeGiovanni PJ; Piel B; Rai P
    Clin Transl Med; 2017 Dec; 6(1):44. PubMed ID: 29230567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-targeted nanomedicines for cancer theranostics.
    Arranja AG; Pathak V; Lammers T; Shi Y
    Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook.
    Mu Q; Yu J; McConnachie LA; Kraft JC; Gao Y; Gulati GK; Ho RJY
    J Drug Target; 2018; 26(5-6):435-447. PubMed ID: 29285948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.